Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 2:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 584 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Injection needle Clear all
Not listed Not applicable Interventional

Korean Medicine for Symptomatic Lumbar Spinal Spondylolisthesis

NCT03107468
View directory record Official record
Conditions
Spondylolisthesis, Lumbosacral Region
Interventions
Mokhuri intensive treatment, Non-surgical conventional standard treatment
Other
Lead sponsor
Kim Ki Ok
Other
Eligibility
19 Years to 78 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Sep 2, 2026, 2:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of US-Guided Paravertebral and Proximal Intercostal Nerve Blocks

NCT02911168
View directory record Official record
Conditions
Pain
Interventions
Proximal Intercostal Block, Paravertebral Block
Procedure
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 2, 2026, 2:07 AM EDT
Active, not recruiting Phase 3 Interventional

Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)

NCT06617429
View directory record Official record
Conditions
Angelman Syndrome
Interventions
GTX-102, Sham-LP
Drug · Procedure
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
4 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
14
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 2, 2026, 2:07 AM EDT
Recruiting Not applicable Interventional

Study to Identify Biomarkers of Oral Cavity Cancer Response to Neoadjuvant Immunotherapy Prior to Definitive Surgery

NCT07343596
View directory record Official record
Conditions
Oral Cavity Cancer
Interventions
Pembrolizumab, Patient-Specific Culture Vessel
Biological · Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 2, 2026, 2:07 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA)

NCT02292537
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
Nusinersen, Sham procedure
Drug · Procedure
Lead sponsor
Biogen
Industry
Eligibility
2 Years to 12 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Sep 2, 2026, 2:07 AM EDT
Completed Not applicable Interventional

Local Infiltration Analgesia Vs. Interscalene Block in Total Shoulder Arthorplasty

NCT04415931
View directory record Official record
Conditions
Shoulder Osteoarthritis, Cuff Tear Arthropathy, Massive Rotator Cuff Tear
Interventions
Local infiltration analgesia, Interscalene block
Procedure
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Sep 2, 2026, 2:07 AM EDT
Completed Phase 2 Interventional Results available

Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)

NCT01527500
View directory record Official record
Conditions
Geographic Atrophy, Age-related Macular Degeneration
Interventions
LFG316, Sham, LFG316 Lower dose
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
55 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
19
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 2, 2026, 2:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Safety Study of Cosmetic Tissue Augmentation in People of Color

NCT01147172
View directory record Official record
Conditions
Wrinkles
Interventions
Elevess
Device
Lead sponsor
Anika Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
9
States / cities
Los Angeles, California • Boca Raton, Florida • Coral Gables, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Sep 2, 2026, 2:07 AM EDT
Recruiting Phase 4 Interventional

Paracervical Block for Pain Reduction in Saline Infusion Sonograms

NCT07048769
View directory record Official record
Conditions
Pain During Saline Infusion Sonogram
Interventions
Lidocaine, Sham paracervical block
Drug · Procedure
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Hartsdale, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 2, 2026, 2:07 AM EDT
Recruiting Not applicable Interventional

Autologous Muscle Fiber Fragment Injections

NCT05396456
View directory record Official record
Conditions
Fecal Incontinence
Interventions
Muscle Fiber Fragment (MFF) Injections
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 2, 2026, 2:07 AM EDT
Terminated Phase 2 Interventional Results available

Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission

NCT03376477
View directory record Official record
Conditions
Multiple Myeloma
Interventions
GM-CSF vaccine, Lenalidomide, Prevnar13, Placebo Prevnar13, Placebo GM-CSF Vaccine
Biological · Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 2, 2026, 2:07 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)

NCT04603937
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
KSI-301, Aflibercept, Sham Procedure
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
18 Years and older
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
40
States / cities
Phoenix, Arizona • Beverly Hills, California • Fullerton, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Sep 2, 2026, 2:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults

NCT03783130
View directory record Official record
Conditions
Human Immunodeficiency Virus Prevention, Human Immunodeficiency Virus (HIV)
Interventions
VRC-HIVRGP096-00-VP, Alum Adjuvant
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Sep 2, 2026, 2:07 AM EDT
Not yet recruiting Phase 3 Interventional

Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

NCT07624513
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Isatuximab, Iberdomide, Bortezomib (B), Dexamethasone, Melphalan, Linvoseltamab, On Body Delivery System (OBDS)
Drug · Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 2, 2026, 2:07 AM EDT
Not listed Not applicable Interventional

Fine Needle Biopsy of Solid Pancreatic Mass Lesions

NCT04085055
View directory record Official record
Conditions
Pancreatic Neoplasms
Interventions
Solid pancreatic mass lesion biopsy
Diagnostic Test
Lead sponsor
AdventHealth
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Sep 2, 2026, 2:07 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND4 Mutations

NCT05293626
View directory record Official record
Conditions
Leber Hereditary Optic Neuropathy (LHON)
Interventions
NR082 Injection, Injection needle
Drug · Device
Lead sponsor
Neurophth Therapeutics Inc
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
3
States / cities
Palo Alto, California • Aurora, Colorado • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Sep 2, 2026, 2:07 AM EDT
Withdrawn Not applicable Interventional

Study of Viscosupplementation for the Treatment of Knee Pain After Menisectomy

NCT00971074
View directory record Official record
Conditions
Arthralgia
Interventions
Hylan G-F 20, Sham Injection
Drug · Other
Lead sponsor
Grant Jones
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Sep 2, 2026, 2:07 AM EDT
Completed Phase 1 Interventional

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

NCT01176474
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
NY-ESO-1 157-165 (165V), Nivolumab, gp100:280-288 (288V), Montanide ISA 51 vegetable grade (VG), Ipilimumab, Apheresis Procedure
Biological · Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
16 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Sep 2, 2026, 2:07 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

ESP vs QL for Total Abdominal Hysterectomy

NCT04074226
View directory record Official record
Conditions
Postoperative Pain
Interventions
Erector Spinae Plane block, Quadratus Lumborum Block
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Sep 2, 2026, 2:07 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Trigger Point Injections Versus Lidocaine Patch for Myofascial Pain in the Emergency Department

NCT05151510
View directory record Official record
Conditions
Myofascial Trigger Point Pain, Myofacial Pain
Interventions
Trigger point injection with 1% lidocaine, Lidocaine patch 5%
Procedure · Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 2, 2026, 2:07 AM EDT
Completed Not applicable Interventional

The Relationship Between Needle Position and Injection Pressure During Femoral Nerve Block

NCT02451813
View directory record Official record
Conditions
Orthopedic Disorders
Interventions
Apposition of needle bevel against femoral nerve
Procedure
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Sep 2, 2026, 2:07 AM EDT
Completed Phase 4 Interventional Results available

Septorhinoplasty Post-operative Pain Control With SPG Nerve Block

NCT05667324
View directory record Official record
Conditions
Deviated Nasal Septum
Interventions
Ropivacaine, Dexamethasone, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 2, 2026, 2:07 AM EDT
Active, not recruiting Not applicable Interventional

Investigating Age Dependence of Fibroblast and Extracellular Matrix Responses to Cross-linked Hyaluronic Acid Filler in Human Skin

NCT06195605
View directory record Official record
Conditions
Photoaging
Interventions
Restylane-L, Vehicle
Device
Lead sponsor
University of Michigan
Other
Eligibility
30 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 2, 2026, 2:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women

NCT02940522
View directory record Official record
Conditions
Comparing Bioavailability When Makena® is Administered in Healthy Post-menopausal Women
Interventions
Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 75 Years · Female only
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
5
States / cities
Anaheim, California • DeLand, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Sep 2, 2026, 2:07 AM EDT